Administration of tobramycin in the beginning of the hemodialysis session

A novel intradialytic dosing regimen

Osama Hussein Kamel Mohamed, Ihab M. Wahba, Suzanne Watnick, Sandra B. Earle, William M. Bennett, James W. Ayres, Myrna Y. Munar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Aminoglycoside antibiotic efficacy is related to peak concentration (Cmax) and postantibiotic effect, whereas toxicity is directly related to body exposure as measured by area under the serum concentration versus time curve (AUC). On the basis of pharmacokinetic simulation models, tobramycin administration during the first 30 min of high-flux hemodialysis achieves similar Cmax but significantly lower AUC and prehemodialysis concentrations compared with conventional dosing in the last 30 min of hemodialysis. Design, setting, participants, and measurements: To test this hypothesis, a pilot study in which five adult chronic hemodialysis patients who were undergoing high-flux dialysis received one dose of tobramycin 1.5 mg/kg intravenously during the first or last 30 min of hemodialysis was conducted. After a 1-mo washout period, patients crossed over to the other treatment schedule. Tobramycin serum concentrations were measured to determine Cmax, interdialytic and intradialytic elimination rate constants and half-lives, AUC, and clearance. Results: Tobramycin administration during the first and last 30 min of hemodialysis resulted in similar Cmax, of 5.63 ± 0.49 and 5.83 ± 0.67 mg/L (P > 0.05) but significantly lower prehemodialysis concentrations of 0.16 ± 0.09 and 2.44 ± 0.43 mg/L (P <0.001) and AUC of 21.06 and 179.23 ± 25.84 mg/h per L (P <0.001), respectively. Conc lusions: Tobramycin administration during the first 30 min of hemodialysis results in similar Cmax, but lower AUC to conventional dosing, which may translate into comparable efficacy but lower toxicity.

Original languageEnglish (US)
Pages (from-to)694-699
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Volume2
Issue number4
DOIs
StatePublished - Jul 2007

Fingerprint

Tobramycin
Renal Dialysis
Area Under Curve
Aminoglycosides
Serum
Dialysis
Appointments and Schedules
Pharmacokinetics
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Medicine(all)

Cite this

Kamel Mohamed, O. H., Wahba, I. M., Watnick, S., Earle, S. B., Bennett, W. M., Ayres, J. W., & Munar, M. Y. (2007). Administration of tobramycin in the beginning of the hemodialysis session: A novel intradialytic dosing regimen. Clinical Journal of the American Society of Nephrology, 2(4), 694-699. https://doi.org/10.2215/CJN.01600407

Administration of tobramycin in the beginning of the hemodialysis session : A novel intradialytic dosing regimen. / Kamel Mohamed, Osama Hussein; Wahba, Ihab M.; Watnick, Suzanne; Earle, Sandra B.; Bennett, William M.; Ayres, James W.; Munar, Myrna Y.

In: Clinical Journal of the American Society of Nephrology, Vol. 2, No. 4, 07.2007, p. 694-699.

Research output: Contribution to journalArticle

Kamel Mohamed, Osama Hussein ; Wahba, Ihab M. ; Watnick, Suzanne ; Earle, Sandra B. ; Bennett, William M. ; Ayres, James W. ; Munar, Myrna Y. / Administration of tobramycin in the beginning of the hemodialysis session : A novel intradialytic dosing regimen. In: Clinical Journal of the American Society of Nephrology. 2007 ; Vol. 2, No. 4. pp. 694-699.
@article{5dfce40f20ce44278a849b7b824af365,
title = "Administration of tobramycin in the beginning of the hemodialysis session: A novel intradialytic dosing regimen",
abstract = "Background: Aminoglycoside antibiotic efficacy is related to peak concentration (Cmax) and postantibiotic effect, whereas toxicity is directly related to body exposure as measured by area under the serum concentration versus time curve (AUC). On the basis of pharmacokinetic simulation models, tobramycin administration during the first 30 min of high-flux hemodialysis achieves similar Cmax but significantly lower AUC and prehemodialysis concentrations compared with conventional dosing in the last 30 min of hemodialysis. Design, setting, participants, and measurements: To test this hypothesis, a pilot study in which five adult chronic hemodialysis patients who were undergoing high-flux dialysis received one dose of tobramycin 1.5 mg/kg intravenously during the first or last 30 min of hemodialysis was conducted. After a 1-mo washout period, patients crossed over to the other treatment schedule. Tobramycin serum concentrations were measured to determine Cmax, interdialytic and intradialytic elimination rate constants and half-lives, AUC, and clearance. Results: Tobramycin administration during the first and last 30 min of hemodialysis resulted in similar Cmax, of 5.63 ± 0.49 and 5.83 ± 0.67 mg/L (P > 0.05) but significantly lower prehemodialysis concentrations of 0.16 ± 0.09 and 2.44 ± 0.43 mg/L (P <0.001) and AUC of 21.06 and 179.23 ± 25.84 mg/h per L (P <0.001), respectively. Conc lusions: Tobramycin administration during the first 30 min of hemodialysis results in similar Cmax, but lower AUC to conventional dosing, which may translate into comparable efficacy but lower toxicity.",
author = "{Kamel Mohamed}, {Osama Hussein} and Wahba, {Ihab M.} and Suzanne Watnick and Earle, {Sandra B.} and Bennett, {William M.} and Ayres, {James W.} and Munar, {Myrna Y.}",
year = "2007",
month = "7",
doi = "10.2215/CJN.01600407",
language = "English (US)",
volume = "2",
pages = "694--699",
journal = "Clinical Journal of the American Society of Nephrology",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - Administration of tobramycin in the beginning of the hemodialysis session

T2 - A novel intradialytic dosing regimen

AU - Kamel Mohamed, Osama Hussein

AU - Wahba, Ihab M.

AU - Watnick, Suzanne

AU - Earle, Sandra B.

AU - Bennett, William M.

AU - Ayres, James W.

AU - Munar, Myrna Y.

PY - 2007/7

Y1 - 2007/7

N2 - Background: Aminoglycoside antibiotic efficacy is related to peak concentration (Cmax) and postantibiotic effect, whereas toxicity is directly related to body exposure as measured by area under the serum concentration versus time curve (AUC). On the basis of pharmacokinetic simulation models, tobramycin administration during the first 30 min of high-flux hemodialysis achieves similar Cmax but significantly lower AUC and prehemodialysis concentrations compared with conventional dosing in the last 30 min of hemodialysis. Design, setting, participants, and measurements: To test this hypothesis, a pilot study in which five adult chronic hemodialysis patients who were undergoing high-flux dialysis received one dose of tobramycin 1.5 mg/kg intravenously during the first or last 30 min of hemodialysis was conducted. After a 1-mo washout period, patients crossed over to the other treatment schedule. Tobramycin serum concentrations were measured to determine Cmax, interdialytic and intradialytic elimination rate constants and half-lives, AUC, and clearance. Results: Tobramycin administration during the first and last 30 min of hemodialysis resulted in similar Cmax, of 5.63 ± 0.49 and 5.83 ± 0.67 mg/L (P > 0.05) but significantly lower prehemodialysis concentrations of 0.16 ± 0.09 and 2.44 ± 0.43 mg/L (P <0.001) and AUC of 21.06 and 179.23 ± 25.84 mg/h per L (P <0.001), respectively. Conc lusions: Tobramycin administration during the first 30 min of hemodialysis results in similar Cmax, but lower AUC to conventional dosing, which may translate into comparable efficacy but lower toxicity.

AB - Background: Aminoglycoside antibiotic efficacy is related to peak concentration (Cmax) and postantibiotic effect, whereas toxicity is directly related to body exposure as measured by area under the serum concentration versus time curve (AUC). On the basis of pharmacokinetic simulation models, tobramycin administration during the first 30 min of high-flux hemodialysis achieves similar Cmax but significantly lower AUC and prehemodialysis concentrations compared with conventional dosing in the last 30 min of hemodialysis. Design, setting, participants, and measurements: To test this hypothesis, a pilot study in which five adult chronic hemodialysis patients who were undergoing high-flux dialysis received one dose of tobramycin 1.5 mg/kg intravenously during the first or last 30 min of hemodialysis was conducted. After a 1-mo washout period, patients crossed over to the other treatment schedule. Tobramycin serum concentrations were measured to determine Cmax, interdialytic and intradialytic elimination rate constants and half-lives, AUC, and clearance. Results: Tobramycin administration during the first and last 30 min of hemodialysis resulted in similar Cmax, of 5.63 ± 0.49 and 5.83 ± 0.67 mg/L (P > 0.05) but significantly lower prehemodialysis concentrations of 0.16 ± 0.09 and 2.44 ± 0.43 mg/L (P <0.001) and AUC of 21.06 and 179.23 ± 25.84 mg/h per L (P <0.001), respectively. Conc lusions: Tobramycin administration during the first 30 min of hemodialysis results in similar Cmax, but lower AUC to conventional dosing, which may translate into comparable efficacy but lower toxicity.

UR - http://www.scopus.com/inward/record.url?scp=34548827732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548827732&partnerID=8YFLogxK

U2 - 10.2215/CJN.01600407

DO - 10.2215/CJN.01600407

M3 - Article

VL - 2

SP - 694

EP - 699

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

SN - 1555-9041

IS - 4

ER -